BioSpace News Archive

Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Bernhard Ehmer, MD, to the Board as a Non-Executive Director.

Immunovant, Inc. today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at LifeSci Partners’ virtual Immunology and Inflammation Symposium, taking place May 10th -11th , 2022.

Synthetic Biologics, Inc. (NYSE American: SYN), today announced an upcoming oral presentation on novel oncolytic adenovirus VCN-11 at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), to be held virtually and in-person from May 16-19, 2022 in Washington, D.C.

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced the presentation of additional positive findings from the ongoing X-linked retinitis pigmentosa (XLRP) Phase 1/2 study of AGTC-501.

RAPT Therapeutics, Inc. today announced the appointments of Gwen Carscadden as Chief Human Resources Officer, Jim Farmer as Vice President of Clinical Operations and Shari Geffon as Vice President of Program and Alliance Management.

Medolife Rx, Inc., a global integrated biotech company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc., announced that it has scheduled a conference call with investors for Thursday, May 12.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, today reports new biomarker and exploratory analysis data from its Phase IIb AIPAC trial.

Amphista and Bristol Myers Squibb to collaborate and leverage Amphista’s proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics.

Unchained Labs, the life sciences company that’s all about getting biologics and gene therapy researchers the right tools for the job, acquired NanoView Biosciences today.

South Rampart Pharma (“South Rampart” or the “Company”), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced it achieved milestones outlined in the Phase I portion of its Small Business Technology Transfer (STTR) grant (1R42NS119103) received from the National Institutes of Health (NIH) and advanced to the Phase II portion of its NIH grant.